Childhood obesity has become a global health crisis, with alarming numbers continuing to rise. With projections indicating that by 2030, an estimated 250 million children could be obese, experts are looking for ways to curb the phenomenon.
According to the World Health Organization, obesity rates have more than tripled worldwide since 1975 and have increased nearly fivefold among children and adolescents.
One proposed solution is the use of weight-loss medications, such as those in the GLP-1 class. Supporters of this approach argue that these drugs can help prevent health complications and improve the quality of life of obese children. On the other hand, critics raise concerns about the long-term effects and potential for addiction to these medications, suggesting that more attention should be paid to treatments based on lifestyle changes.
This debate has divided the scientific community, raising important questions about health, ethics, and responsibility in treating childhood obesity.
Debate over the use of weight loss medications in children
Arguments in favor:
•Scientists and doctors believe that these medications can stop obesity in its early stages.
•Many overweight teens face bullying and isolation. A study of nearly 7,000 obese youths showed that those who used this type of medication, known as GLP-1, had a lower risk of having suicidal thoughts or attempts.
Arguments against:
• While treating obesity in adults can be seen as correcting past mistakes, using medications in children can make them dependent on them for life.
•Researchers worry that it is not yet known how these medications affect children's developing bodies and what the long-term effects may be.
•Critics compare their use to antidepressants, which are often used as a quick fix for complex mental health problems, avoiding efforts to address the real causes of the problem.
